Skin Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Skin Cancer, including details on identification, causes, prevention, treatment.

Volume 2 (2005), Issue 6 (June)

1. Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy.
   Ann Surg Oncol, 12(6): 429-39. [Abstract] [Full-text]
2. Phase I trial combining gemcitabine and treosulfan in advanced cutaneous and uveal melanoma patients.
   Br J Cancer, 92(11): 1997-2003. [Abstract] [Full-text]
3. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas.
   Ann Surg Oncol, 12(6): 449-58. [Abstract] [Full-text]
4. Sentinel lymph node tumor load: an independent predictor of additional lymph node involvement and survival in melanoma.
   Ann Surg Oncol, 12(6): 440-8. [Abstract] [Full-text]
5. Prevention of mouse skin tumor promotion by dietary energy restriction requires an intact adrenal gland and glucocorticoid supplementation restores inhibition.
   Carcinogenesis, 26(6): 1077-84. [Abstract] [Full-text]
6. Assessment of 3 xeroderma pigmentosum group C gene polymorphisms and risk of cutaneous melanoma: a case-control study.
   Carcinogenesis, 26(6): 1085-90. [Abstract] [Full-text]
7. ALK-positive neutrophil-rich variant of anaplastic large cell lymphoma diagnosed after head trauma.
   Onkologie, 28(6): 356-8. [Abstract] [Full-text]
8. Merkel cell carcinoma: improved outcome with adjuvant radiotherapy.
   ANZ J Surg, 75(5): 275-81. [Abstract] [Full-text]
9. Community perceptions of suspicious pigmented skin lesions: are they accurate when compared to general practitioners?
   Cancer Detect Prev, 29(3): 267-75. [Abstract] [Full-text]
10. Control of melanoma cell invasion by type IV collagen.
    Cancer Detect Prev, 29(3): 260-6. [Abstract] [Full-text]
11. Effect of polymorphisms in XPD, RAI, ASE-1 and ERCC1 on the risk of basal cell carcinoma among Caucasians after age 50.
    Cancer Detect Prev, 29(3): 209-14. [Abstract] [Full-text]
12. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models.
    Cancer Chemother Pharmacol, 56(2): 126-37. [Abstract] [Full-text]
13. Metastatic malignant melanoma presenting as pancytopenia in a three-year-old boy.
    Pediatr Blood Cancer, 45(1): 60-3. [Abstract] [Full-text]
14. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative.
    Cancer Chemother Pharmacol, 56(2): 115-25. [Abstract] [Full-text]
15. The spontaneous regression of tufted angioma. A case of regression after two recurrences and a review of 27 cases reported in the literature.
    Dermatology, 210(4): 346-8. [Abstract] [Full-text]
16. Atypical poorly differentiated cutaneous T-cell lymphoma with an angiocentric growth pattern presenting histologically as vasculitis.
    Dermatology, 210(4): 341-5. [Abstract] [Full-text]
17. Ichthyosiform mycosis fungoides: report of a case associated with IgA nephropathy.
    Dermatology, 210(4): 324-8. [Abstract] [Full-text]
18. Extramammary Paget's disease not only mimicking but also accompanying condyloma acuminatum. A case report.
    Dermatology, 210(4): 315-8. [Abstract] [Full-text]
19. Genetic variation in XPD, sun exposure, and risk of skin cancer.
    Cancer Epidemiol Biomarkers Prev, 14(6): 1539-44. [Abstract] [Full-text]
20. A phase II study of bortezomib in the treatment of metastatic malignant melanoma.
    Cancer, 103(12): 2584-9. [Abstract] [Full-text]
21. Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study.
    Cancer, 103(12): 2590-7. [Abstract] [Full-text]
22. Quantifying levels of p53 mutation in mouse skin tumors.
    Environ Mol Mutagen, 45(5): 427-34. [Abstract] [Full-text]
23. Basal cell carcinoma arising from a keratinous cyst of the skin: a case report and review of the literature.
    Med Mol Morphol, 38(2): 130-3. [Abstract] [Full-text]
24. Pattern of regional metastases from cutaneous squamous cell carcinoma of the head and neck.
    Otolaryngol Head Neck Surg, 132(6): 852-6. [Abstract] [Full-text]
25. Preliminary study of the lived experience of exercise for cancer survivors.
    Eur J Oncol Nurs, 9(2): 155-66. [Abstract] [Full-text]
26. Clinical diagnosis of skin tumours: how good are we?
    ANZ J Surg, 75(6): 415-20. [Abstract] [Full-text]
27. An analysis of risk factors for cutaneous melanoma by anatomical site (Australia).
    Cancer Causes Control, 16(3): 193-9. [Abstract] [Full-text]
28. Pigmentation in basal cell carcinoma involves enhanced endothelin-1 expression.
    Exp Dermatol, 14(7): 528-34. [Abstract] [Full-text]
29. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.
    J Clin Oncol, 23(17): 3886-96. [Abstract] [Full-text]
30. Cutaneous metastases from a hypopharyngeal malignancy.
    J Laryngol Otol, 119(4): 319-21. [Abstract] [Full-text]
31. Different phenotypes in Muir-Torre syndrome: clinical and biomolecular characterization in two Italian families.
    Br J Dermatol, 152(6): 1335-8. [Abstract] [Full-text]
32. Paraneoplastic pityriasis lichenoides in cutaneous lymphoma: case report and review of the literature on paraneoplastic reactions of the skin in lymphoma and leukaemia.
    Br J Dermatol, 152(6): 1327-31. [Abstract] [Full-text]
33. Outcomes and pathological review of a cohort of children with melanoma.
    Br J Dermatol, 152(6): 1321-3. [Abstract] [Full-text]
34. Comparative analysis of the expression of ERBIN and Erb-B2 in normal human skin and cutaneous carcinomas.
    Br J Dermatol, 152(6): 1248-55. [Abstract] [Full-text]
35. Human papillomaviruses of the mucosal type are present in some cases of extragenital Bowen's disease.
    Br J Dermatol, 152(6): 1243-7. [Abstract] [Full-text]
36. Management of melanoma metastasis to the breast: case series and review of the literature.
    Br J Dermatol, 152(6): 1206-10. [Abstract] [Full-text]
37. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
    Br J Dermatol, 152(6): 1199-205. [Abstract] [Full-text]
38. Molecular aetiology and pathogenesis of basal cell carcinoma.
    Br J Dermatol, 152(6): 1108-24. [Abstract] [Full-text]
39. Solitary glomeruloid haemangioma without POEMS syndrome.
    J Cutan Pathol, 32(6): 449-52. [Abstract] [Full-text]
40. Basal cell carcinoma with matrical differentiation in a transplant patient: a case report and review of the literature.
    J Cutan Pathol, 32(6): 445-8. [Abstract] [Full-text]
41. Clear cell 'sugar' tumor (PEComa) of the skin: a case report.
    J Cutan Pathol, 32(6): 441-4. [Abstract] [Full-text]
42. Juvenile hyaline fibromatosis: a case report.
    J Cutan Pathol, 32(6): 438-40. [Abstract] [Full-text]
43. Hypertext atlas of dermatopathology with expert system for epithelial tumors of the skin.
    J Cutan Pathol, 32(6): 433-7. [Abstract] [Full-text]
44. Histologic variants of fibrous papule.
    J Cutan Pathol, 32(6): 424-8. [Abstract] [Full-text]
45. Lymphoepithelioma-like carcinoma of the skin with spindle cell differentiation.
    J Cutan Pathol, 32(6): 419-23. [Abstract] [Full-text]
46. Cellular digital fibromas: distinctive CD34-positive lesions that may mimic dermatofibrosarcoma protuberans.
    J Cutan Pathol, 32(6): 413-8. [Abstract] [Full-text]
47. Histologic similarities between lentigo maligna and dysplastic nevus: importance of clinicopathologic distinction.
    J Cutan Pathol, 32(6): 405-12. [Abstract] [Full-text]
48. HLA-G expression in basal cell carcinomas of the skin recurring after radiotherapy.
    Clin Exp Dermatol, 30(4): 422-5. [Abstract] [Full-text]
49. Disseminated Kaposi's sarcoma associated with idiopathic CD4+ lymphocytopenia and low dose steroid therapy.
    Clin Exp Dermatol, 30(4): 395-7. [Abstract] [Full-text]
50. Composite cutaneous haemangioendothelioma: case report and review of the literature.
    Clin Exp Dermatol, 30(4): 385-7. [Abstract] [Full-text]
51. Two squamous cell carcinomas arising in a linear epidermal naevus in a 28-year-old female.
    Clin Exp Dermatol, 30(4): 382-4. [Abstract] [Full-text]
52. Narrow-band UVB in the treatment of early stage mycosis fungoides: report of 16 patients.
    Clin Exp Dermatol, 30(4): 376-8. [Abstract] [Full-text]
53. Sun protection initiatives in Cornwall.
    Clin Exp Dermatol, 30(4): 340-3. [Abstract] [Full-text]
54. Multiple cutaneous acral metastases in a woman with breast adenocarcinoma treated with pegylated liposomal doxorubicin: incidental or aetiological association?
    Eur J Cancer Care (Engl), 14(3): 267-71. [Abstract] [Full-text]
55. Gastrointestinal and cutaneous AIDS-related Kaposi's sarcoma: different activity of liposomal doxorubicin according to location of lesions.
    Eur J Cancer Care (Engl), 14(3): 264-6. [Abstract] [Full-text]
56. Ultraviolet radiation-induced impairment of tumor rejection is enhanced in xeroderma pigmentosum a gene-deficient mice.
    J Invest Dermatol, 124(6): 1313-7. [Abstract] [Full-text]
57. Search for germline alterations in CDKN2A/ARF and CDK4 of 42 Jewish melanoma families with or without neural system tumours.
    Br J Cancer, 92(12): 2278-85. [Abstract] [Full-text]
58. Analysis of differential gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays.
    Br J Cancer, 92(12): 2249-61. [Abstract] [Full-text]
59. Early growth response 1 acts as a tumor suppressor in vivo and in vitro via regulation of p53.
    Cancer Res, 65(12): 5133-43. [Abstract] [Full-text]
60. Cutaneous metastases of a bronchial adenocarcinoma in a cat.
    Vet Dermatol, 16(3): 183-6. [Abstract] [Full-text]
61. Angiosarcoma after breast-conserving therapy: fine-needle aspiration biopsy, immunocytochemistry, and clinicopathologic correlates.
    Cancer, 105(3): 145-51. [Abstract] [Full-text]
62. The association of Medicare health care delivery systems with stage at diagnosis and survival for patients with melanoma.
    Arch Dermatol, 141(6): 753-7. [Abstract] [Full-text]
63. Early detection of thick melanomas in the United States: beware of the nodular subtype.
    Arch Dermatol, 141(6): 745-50. [Abstract] [Full-text]
64. The role of microsatellites as a prognostic factor in primary malignant melanoma.
    Arch Dermatol, 141(6): 739-42. [Abstract] [Full-text]
65. Impact of thorough block sampling in the histologic evaluation of melanomas.
    Arch Dermatol, 141(6): 734-6. [Abstract] [Full-text]
66. Variation in the diagnosis, treatment, and management of melanoma in situ: a survey of US dermatologists.
    Arch Dermatol, 141(6): 723-9. [Abstract] [Full-text]
67. Effect of common B-RAF and N-RAS mutations on global gene expression in melanoma cell lines.
    Carcinogenesis, 26(7): 1224-32. [Abstract] [Full-text]
68. Tumour regulation of fibroblast hyaluronan expression: a mechanism to facilitate tumour growth and invasion.
    Carcinogenesis, 26(7): 1215-23. [Abstract] [Full-text]
69. Axillary apocrine carcinoma with benign apocrine tumours: a case report involving a pathological and immunohistochemical study and review of the literature.
    J Clin Pathol, 58(7): 757-61. [Abstract] [Full-text]
70. Transformed dermatofibrosarcoma protuberans: a clinicopathological study of eight cases.
    J Clin Pathol, 58(7): 751-6. [Abstract] [Full-text]
71. The use of LYVE-1 antibody for detecting lymphatic involvement in patients with malignant melanoma of known sentinel node status.
    J Clin Pathol, 58(7): 715-21. [Abstract] [Full-text]
72. Scalp and forehead reconstruction.
    Clin Plast Surg, 32(3): 377-90, vi-vii. [Abstract] [Full-text]
73. Microarray profiles of human basal cell carcinoma: insights into tumor growth and behavior.
    J Dermatol Sci, 39(1): 39-51. [Abstract] [Full-text]
74. WT1 expression in angiogenic tumours of the skin.
    Histopathology, 47(1): 67-73. [Abstract] [Full-text]
75. Bioluminescent imaging of melanoma in live mice.
    J Invest Dermatol, 125(1): 159-65. [Abstract] [Full-text]
76. Human papillomavirus gene expression in cutaneous squamous cell carcinomas from immunosuppressed and immunocompetent individuals.
    J Invest Dermatol, 125(1): 98-107. [Abstract] [Full-text]
77. Human papillomavirus-DNA loads in actinic keratoses exceed those in non-melanoma skin cancers.
    J Invest Dermatol, 125(1): 93-7. [Abstract] [Full-text]
78. Two new XPD patients compound heterozygous for the same mutation demonstrate diverse clinical features.
    J Invest Dermatol, 125(1): 86-92. [Abstract] [Full-text]
79. The role of toll-like receptors in the pathogenesis and treatment of dermatological disease.
    J Invest Dermatol, 125(1): 1-8. [Abstract] [Full-text]
80. Immunological detection of altered signaling molecules involved in melanoma development.
    Cancer Metastasis Rev, 24(2): 357-66. [Abstract] [Full-text]
81. Rb/E2F: a two-edged sword in the melanocytic system.
    Cancer Metastasis Rev, 24(2): 339-56. [Abstract] [Full-text]
82. De-regulation of ubiquitin-dependent proteolysis and the pathogenesis of malignant melanoma.
    Cancer Metastasis Rev, 24(2): 329-38. [Abstract] [Full-text]
83. Targeting STAT3 affects melanoma on multiple fronts.
    Cancer Metastasis Rev, 24(2): 315-27. [Abstract] [Full-text]
84. Role of nuclear factor-kappa B in melanoma.
    Cancer Metastasis Rev, 24(2): 301-13. [Abstract] [Full-text]
85. Protein kinase C in melanoma.
    Cancer Metastasis Rev, 24(2): 287-300. [Abstract] [Full-text]
86. Functional and therapeutic significance of Akt deregulation in malignant melanoma.
    Cancer Metastasis Rev, 24(2): 273-85. [Abstract] [Full-text]
87. SKI pathways inducing progression of human melanoma.
    Cancer Metastasis Rev, 24(2): 265-72. [Abstract] [Full-text]
88. Bone morphogenetic proteins in melanoma: angel or devil?
    Cancer Metastasis Rev, 24(2): 251-63. [Abstract] [Full-text]
89. A Wnt-er wonderland--the complexity of Wnt signaling in melanoma.
    Cancer Metastasis Rev, 24(2): 237-50. [Abstract] [Full-text]
90. Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration?
    Cancer Metastasis Rev, 24(2): 223-36. [Abstract] [Full-text]
91. Integrin signaling in malignant melanoma.
    Cancer Metastasis Rev, 24(2): 195-222. [Abstract] [Full-text]

© 2004-2008 Skin Cancer Research Today. All Rights Reserved.